Alumis Inc. (Nasdaq: ALMS) has announced significant advancements in its clinical trials for Envudeucitinib, a next-generation oral therapy aimed at treating moderate-to-severe plaque psoriasis. The results from two Phase 3 trials, ONWARD1 and ONWARD2, presented at the 2026 American Academy of Dermatology Annual Meeting, indicate that Envudeucitinib achieved robust improvements in skin clearance and quality of life for patients. By Week 16, 68% of patients treated with Envudeucitinib reached a Psoriasis Area and Severity Index (PASI) 90 response, with 41% achieving complete skin clearance (PASI 100). These results underscore the drug's potential as a leading oral therapy for psoriasis, particularly given its favorable safety profile consistent with earlier Phase 2 studies. The company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the second half of 2026, further solidifying its commitment to bringing this innovative treatment to market. The positive outcomes from these trials not only highlight the efficacy of Envudeucitinib but also reflect Alumis's strategic focus on developing targeted therapies for immune-mediated diseases. The company is also exploring a once-daily formulation and a pediatric development plan for Envudeucitinib, aiming to enhance patient accessibility and treatment options. As the clinical program progresses, Alumis remains dedicated to evaluating the long-term efficacy and safety of Envudeucitinib, with one-year Phase 3 data expected later this year. Investors and stakeholders are encouraged to stay tuned for further updates as the company continues to navigate the regulatory landscape and advance its clinical pipeline.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.